Self-administering bimekizumab via syringe, auto-injector sees similar success, safety

摘要

Psoriasis patients who self-administer bimekizumab experienced similar levels of comfort and success with both safety syringes and auto-injectors, according to two studies. "This multicenter study looked at how people did with a 1 mL safety syringe, the typical, old-fashioned syringes people are used to, vs. an autoinjector, which is a larger apparatus, but is very easy to use by just pressing a button," Jerry Bagel, MD, MS, of the Psoriasis Treatment Center of Central New Jersey and the paper's lead author, told Healio. Sub-studies of the phase 3 open-label extension BE BRIGHT study, the DV0002 and DV0006 studies valuated the safety and efficacy of self-administered bimekizumab, as well as patient satisfaction and experience.